Protocol Ledger

NCT03638128 · Phase III · TERMINATED

Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta

Interventional Phase III clinical trial protocol NCT03638128 sponsored by Amgen in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-07-26 Enrollment: 75 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03638128
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)75 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03638128
Protocol FieldVerified Registry Value
NCT IdentifierNCT03638128
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment75 participants (ACTUAL)
Registered Start Date2018-07-26
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03638128
Hospital Research SiteLocationSite Profile
Children's Hospital Los AngelesLos Angeles, CAOpen Hospital Dossier ->
The Hospital for Sick ChildrenToronto, CanadaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI